Spermine Regulates Immune and Signal Transduction Dysfunction in Diabetic Cardiomyopathy.
Animals
Diabetic Cardiomyopathies
/ immunology
Down-Regulation
Female
Gene Regulatory Networks
Immunity
/ drug effects
Male
Mice
Mice, Inbred C57BL
Myocardium
/ metabolism
RNA-Binding Proteins
/ genetics
Signal Transduction
Spermine
/ pharmacology
Transcription Factors
/ genetics
Transcriptome
Up-Regulation
RNA sequencing
diabetic cardiomyopathy
immune system
signal transduction
spermine
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2021
2021
Historique:
received:
13
07
2021
accepted:
30
12
2021
entrez:
17
2
2022
pubmed:
18
2
2022
medline:
19
3
2022
Statut:
epublish
Résumé
Diabetic cardiomyopathy (DCM) is a specific form of cardiomyopathy that is independent of coronary artery disease and hypertension. Exploring the transcriptomics of DCM is of great significance for understanding the biology of the disease and for guiding new therapeutic targets for the potential therapeutic effect of spermine (SPM). By using a mouse DCM model, we analyzed the transcriptome of the myocardium, before/after treatment with SPM. Using RNA sequencing (RNA-seq), we identified 1,318 differentially expressed genes (DEGs), with 636 being upregulated and 682 being downregulated in DCM compared to control check (CK). We then identified 1,393 DEGs, with 887 being upregulated and 506 being downregulated in SPM compared to DCM. Kyoto Encyclopedia of Genes And Genomes (KEGG) analysis demonstrated that the DEGs were significantly enriched in the immune system and signal transduction-related pathways. UpSet Venn analysis showed that 174 DEGs in DCM could be reversed by SPM, with 45 candidates related to immune system and related signal transduction pathways. Trend analysis demonstrated the dynamic changes in gene levels in DCM and SPM treatment, shown as 49 immune and signal transduction-related candidates were significantly enriched in some classical pathways, such as complement and coagulation cascades and phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)-protein kinase B (Akt) signaling pathway. To further reveal the protective mechanism of SPM to DCM, we predicted 14 overlapped transcription factors (TFs) and their co-factors involved in gene transcription regulation and showed gene interaction with Cytoscape. The biomarkers and canonical pathways identified in this study may hold the key to understanding the mechanisms of DCM pathobiology and providing new targets for the therapeutic effect of SPM against DCM by targeting abnormal immune response and signal transduction.
Sections du résumé
Background
Diabetic cardiomyopathy (DCM) is a specific form of cardiomyopathy that is independent of coronary artery disease and hypertension. Exploring the transcriptomics of DCM is of great significance for understanding the biology of the disease and for guiding new therapeutic targets for the potential therapeutic effect of spermine (SPM).
Methods and Results
By using a mouse DCM model, we analyzed the transcriptome of the myocardium, before/after treatment with SPM. Using RNA sequencing (RNA-seq), we identified 1,318 differentially expressed genes (DEGs), with 636 being upregulated and 682 being downregulated in DCM compared to control check (CK). We then identified 1,393 DEGs, with 887 being upregulated and 506 being downregulated in SPM compared to DCM. Kyoto Encyclopedia of Genes And Genomes (KEGG) analysis demonstrated that the DEGs were significantly enriched in the immune system and signal transduction-related pathways. UpSet Venn analysis showed that 174 DEGs in DCM could be reversed by SPM, with 45 candidates related to immune system and related signal transduction pathways. Trend analysis demonstrated the dynamic changes in gene levels in DCM and SPM treatment, shown as 49 immune and signal transduction-related candidates were significantly enriched in some classical pathways, such as complement and coagulation cascades and phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)-protein kinase B (Akt) signaling pathway. To further reveal the protective mechanism of SPM to DCM, we predicted 14 overlapped transcription factors (TFs) and their co-factors involved in gene transcription regulation and showed gene interaction with Cytoscape.
Conclusion
The biomarkers and canonical pathways identified in this study may hold the key to understanding the mechanisms of DCM pathobiology and providing new targets for the therapeutic effect of SPM against DCM by targeting abnormal immune response and signal transduction.
Identifiants
pubmed: 35173678
doi: 10.3389/fendo.2021.740493
pmc: PMC8842652
doi:
Substances chimiques
RNA-Binding Proteins
0
Transcription Factors
0
Spermine
2FZ7Y3VOQX
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
740493Informations de copyright
Copyright © 2022 Wei, Sun, Liang, Che, Wang, Shi and Fan.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Br J Pharmacol. 2020 Feb;177(4):836-856
pubmed: 30734268
Biochem Pharmacol. 2016 May 1;107:1-13
pubmed: 26686579
BMC Genomics. 2018 May 22;19(1):377
pubmed: 29783952
Nucleic Acids Res. 2014 Oct;42(18):11275-90
pubmed: 25232095
Eur J Heart Fail. 2017 Nov;19(11):1379-1389
pubmed: 28891154
Am J Physiol Endocrinol Metab. 2019 Aug 1;317(2):E284-E297
pubmed: 31184932
Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2019 Sep;35(5):385-389
pubmed: 31894667
Diabetologia. 2018 Jan;61(1):21-28
pubmed: 28776083
Bioinformatics. 2018 Sep 1;34(17):i884-i890
pubmed: 30423086
Molecules. 2018 Jun 19;23(6):
pubmed: 29921764
Adv Exp Med Biol. 2017;1003:3-14
pubmed: 28667551
Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361
pubmed: 27899662
Cell Biol Int. 2020 Aug;44(8):1660-1670
pubmed: 32304136
Circ Res. 2019 Apr 12;124(8):1160-1162
pubmed: 30973809
Cell Physiol Biochem. 2016;38(2):531-44
pubmed: 26828926
Biochem J. 2016 Oct 1;473(19):2937-53
pubmed: 27679855
Innate Immun. 2020 Jan;26(1):4-14
pubmed: 31180799
Redox Biol. 2020 May;32:101514
pubmed: 32234613
Cardiovasc Drugs Ther. 2021 Feb;35(1):73-85
pubmed: 32918657
Adv Exp Med Biol. 2017;1003:121-144
pubmed: 28667557
IUBMB Life. 2009 Sep;61(9):880-94
pubmed: 19603518
Exp Biol Med (Maywood). 2016 Aug;241(14):1505-15
pubmed: 27190250
Int J Mol Med. 2021 Mar;47(3):
pubmed: 33537831
Genome Biol. 2014;15(12):550
pubmed: 25516281
Heart Fail Rev. 2019 Mar;24(2):279-299
pubmed: 30349977
Am J Physiol Heart Circ Physiol. 2019 Aug 1;317(2):H264-H275
pubmed: 31100011
Nat Rev Cardiol. 2019 Nov;16(11):661-674
pubmed: 31186539
Int J Mol Sci. 2019 Jul 05;20(13):
pubmed: 31284374
ESC Heart Fail. 2021 Aug;8(4):2637-2646
pubmed: 34013670
Nat Methods. 2008 Jul;5(7):621-8
pubmed: 18516045
J Cell Biochem. 2016 Dec;117(12):2693-2696
pubmed: 27191703